Vir Bio: 88% HDV RNA undetectable at Week 96 in combo arm; cash ~$781M, runway to Q4 2027

Vir Biotechnology, Inc.

Phase 2 SOLSTICE: 88% (21/24) of combo arm achieved undetectable HDV RNA at Week 96 vs 46% (11/24) monotherapy.
No grade 3+ treatment-related AEs in combo arm; generally mild/moderate and transient.
Cash, cash equivalents & investments ~$781M at Dec 31, 2025; runway extended into Q4 2027 via Norgine deal.
ECLIPSE 1 Phase 3 topline data expected Q4 2026; ECLIPSE 2/3 top-line in Q1 2027.
VIR-5500 Phase 1 data in prostate cancer to be presented at ASCO GU Feb 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.